GlassScriptPhysician profile
Mallory Dixon
NPI 1396224754
$7,242.87
in general payments reported to CMS, 2019-2025
40 companies · $2,646 in 2025
The $2,646 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.44 · 2022: $1,926 · 2023: $1,390 · 2024: $1,252 · 2025: $2,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,209 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,209.18 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.76 | 2022-2025 | |
| Novo Nordisk INC | $855.90 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $637.27 | 2022-2025 | Omvoh, Mounjaro, Zepbound |
| Janssen Biotech, INC. | $585.95 | 2024-2025 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $379.22 | 2022-2024 | Farxiga, Breztri, Evusheld |
| Takeda Pharmaceuticals U.S.A., INC. | $275.05 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Glaxosmithkline, LLC. | $266.27 | 2022-2024 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $237.02 | 2024-2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $216.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $210.87 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $209.92 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.93 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $157.89 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Amarin Pharma, INC. | $154.67 | 2022 | |
| Qol Medical, LLC | $151.61 | 2024-2025 | Sucraid, Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $146.52 | 2025 | |
| Amgen INC. | $124.04 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $108.10 | 2022-2024 | |
| Gilead Sciences, INC. | $105.25 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $103.25 | 2022-2023 | Livalo, Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $96.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $84.97 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $84.33 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $70.32 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.67 | 2025 | Xifaxan, Plenvu |
| Dexcom, INC. | $63.92 | 2022-2023 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $56.68 | 2025 | Iqirvo |
| Enterra Medical, INC. | $55.66 | 2024 | |
| Nevro Corp. | $53.76 | 2023-2024 | Senza |
| Boston Scientific Corporation | $47.83 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Celltrion USA INC. | $44.58 | 2025 | Vegzelma |
| Otsuka America Pharmaceutical, INC. | $41.88 | 2022-2023 | Rexulti |
| Corcept Therapeutics | $40.79 | 2023-2024 | Korlym |
| Tris Pharma INC | $34.14 | 2023-2024 | Dyanavel Xr |
| Evoke Pharma, INC. | $32.94 | 2025 | |
| Horizon Therapeutics Plc | $29.01 | 2022 | |
| Genentech USA, INC. | $28.44 | 2021 | |
| Esperion Therapeutics, INC. | $19.02 | 2022 | |
| Vivus LLC | $15.89 | 2025 | Qsymia |
| Lundbeck LLC | $14.38 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.